Eikon Therapeutics, Inc. (EIKN)

NASDAQ: EIKN · Real-Time Price · USD

9.44

-0.46 (-4.65%)

At close: Apr 6, 2026, 4:00 PM EDT

9.44

0.00 (0.00%)

After-hours: Apr 6, 2026, 5:26 PM EDT

Eikon Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Selling, General & Admin	67.11	55.81	58.48
Research & Development	247.32	204.54	207.26
Operating Expenses	314.43	260.34	265.74
Operating Income	-314.43	-260.34	-265.74
Interest Expense	-0.84	-0.03	-0.04
Interest & Investment Income	15.57	16.56	23.74
Other Non Operating Income (Expenses)	-0.03	-0	0.04
EBT Excluding Unusual Items	-299.73	-243.81	-242
Merger & Restructuring Charges	-3.29	-	-
Asset Writedown	-21.23	-	-
Pretax Income	-324.25	-243.81	-242
Net Income	-324.25	-243.81	-242
Preferred Dividends & Other Adjustments	9.4	-	-
Net Income to Common	-333.64	-243.81	-242
Shares Outstanding (Basic)	3	3	2
Shares Outstanding (Diluted)	3	3	2
Shares Change (YoY)	14.85%	24.35%	-
EPS (Basic)	-115.29	-96.76	-119.43
EPS (Diluted)	-115.29	-96.76	-119.43
Free Cash Flow	-235.26	-219.6	-219.36
Free Cash Flow Per Share	-81.29	-87.16	-108.26
EBITDA	-295.55	-245.34	-254.31
D&A For EBITDA	18.87	15.01	11.43
EBIT	-314.43	-260.34	-265.74

Updated Jan 9, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q